EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 26 October 2017

News

25102017 Industry and research associations call for maintaining EU Institutional Public Private...
25 October 2017

Institutional Public Private Partnership (IPPP): a high value added funding instrument Read more

Blogs

With over 7,000 medicines in development, new treatments will continue to change patients’ lives, slowing disease progression, avoiding illness and reducing overall costs for healthcare systems. But developing a new medicine is a long, complex and risky process with no guarantees of success. Over the coming weeks, we look at a number of new medicines and the role that pharmaceutical incentives (or IP) have played in their development.

26102017 Incentives, IP and smaller companies – the story of ProAxsis
26 October 2017

The development pipeline of ProAxsis: continued innovation fostered by incentives Read more

26102017 Hunter syndrome - Mucopolysaccharidosis Type II – EU Incentives Behind OMPs
26 October 2017

The impact of incentives under the EU OMP Regulation Read more

Events

19 July 2017 War on Cancer – a patient’s journey
21 November 2017 (The HAC, London, UK)

3rd annual conference organised by The Economist Events Read more

14 July 2017 1st European Alliance for Personalised Medicine Congress
27 November 2017 (Belfast, Northern Ireland)

Personalising Your Health: A Global Imperative! Read more

We published

Working together with patient groups
11 October 2017 (Publications)

A publication from the Patient Think Tank to provide guidance for collaboration Read more

Health Collaboration Guide 2017
26 October 2017 (Publications)

Showcasing best practice collaborations between patient organisations and industry, but also local authorities, governments,... Read more

What we are reading

Researchers agree to improve neurology/Alzheimer’s drug development
On 25 October 2017 (AlphaGalileo)

European researchers today launched an ambitious project to tackle some of the major problems of developing new drugs... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu